Mobile

Multi-center, randomized, double-blind, 5-arm parallel group, placebo controlled 4 week study to investigate the safety, tolerability and efficacy of two doses each (near to maximum tolerated dose and...

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001122-13

Multi-center, randomized, double-blind, 5-arm parallel group, placebo controlled 4 week study to investigate the safety, tolerability and efficacy of two doses each (near to maximum tolerated dose and lower dose) of RO5093151 administered twice daily (BID regimen) and RO5027838 administered once daily (QD regimen) in patients with type 2 diabetes mellitus on a stable dose of metformin

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To measure the effect of the two 11β-HSD1 inhibitors RO5093151 and RO5027838 on mean daily plasma glucose (change from baseline at Week 4) in type 2 diabetic patients treated with a stable dose of metformin compared to placebo

Critère d'inclusion

  • Type 2 Diabetes (T2D)

Liens